Decitabine: A historical review of the development of an epigenetic drug

Annals of Hematology, Supplement

Volumn 84, Issue 13, 2005, Pages 3-8

  de Vos, Dick ^a   van Overveld, Wendy ^a  

^a TEVA Pharmachemie   (Netherlands)

Author keywords

AML; CML stem cell; Hypomethylation; MDS; Sickle cell

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AMSACRINE; AZACITIDINE; BUSULFAN; CISPLATIN; CREATININE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; HYDROXYUREA; IDARUBICIN; MESNA; DNA METHYLTRANSFERASE; DRUG DERIVATIVE; DNA; DNA METHYLTRANSFERASE INHIBITOR; HEMOGLOBIN F; HISTONE DEACETYLASE INHIBITOR;

ABNORMAL SUBSTRATE CONCENTRATION IN BLOOD; ACUTE GRANULOCYTIC LEUKEMIA; ADULT RESPIRATORY DISTRESS SYNDROME; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CYTOTOXICITY; DEMETHYLATION; DOSE RESPONSE; DRUG FATALITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; FATIGUE; GENETIC EPIGENESIS; HERPES SIMPLEX; HUMAN; LEUKOPENIA; LUNG TOXICITY; MYELODYSPLASTIC SYNDROME; NAUSEA; PRIORITY JOURNAL; REGISTRATION; REVIEW; SICKLE CELL ANEMIA; SOLID TUMOR; THALASSEMIA; VOMITING; ARTICLE; CHEMISTRY; DRUG ANTAGONISM; DRUG DESIGN; DRUG EFFECT; HISTORY; IMMUNOSUPPRESSIVE TREATMENT; METHODOLOGY; ACUTE LEUKEMIA; CANCER RELAPSE; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CONTINUOUS INFUSION; DISEASE SEVERITY; DNA METHYLATION; DRUG CYTOTOXICITY; DRUG DOSE REGIMEN; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG TREATMENT FAILURE; EPIGENETICS; GRAFT DYSFUNCTION; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HERPES SIMPLEX VIRUS 2; HIGH RISK PATIENT; LEUKEMIA; LIVER DYSFUNCTION; LONG TERM EXPOSURE; LUNG NON SMALL CELL CANCER; NEUROTOXICITY; PARANASAL SINUS CARCINOMA; PROSTATE CANCER; SIDE EFFECT; STEM CELL TRANSPLANTATION; UTERINE CERVIX CANCER; VIRUS REACTIVATION; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CHRONIC GRANULOCYTIC LEUKEMIA; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CYTOGENETICS; DRUG INTERMITTENT THERAPY; LIVER FUNCTION TEST; LOW DRUG DOSE; META ANALYSIS; MONOTHERAPY; OUTCOMES RESEARCH; PHARMACOGENETICS; SYSTEMATIC REVIEW;

ANEMIA, SICKLE CELL; AZACITIDINE; DNA MODIFICATION METHYLASES; DRUG DESIGN; EPIGENESIS, GENETIC; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MYELODYSPLASTIC SYNDROMES; TRANSPLANTATION CONDITIONING;

EID: 29144517352     PISSN: 09458077     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-005-0008-x     Document Type: Review

References (51)

1. Abbruzzese J, Raber M, Vrijhof W et al (1991) A phase I trial of laboratory derived synergistic chemotherapeutic (sc) combination: 2′ deoxy-5-azacytidine (DAC) and cisplatin (CDDP). Proc Am Assoc Cancer Res 32:204 (abstr 1219)
2. Abele R, Clavel M, Dodion P, Bruntsch U, Gundersen S, Smyth J, Renard J, van Glabbeke M, Pinedo HM (1987) The EORTC early clinical trials group experience with 5-aza-2′-deoxycytidine (NSC 127716) in patients with colorectal, head and neck, renal carcinomas and malignant melanomas. Eur J Cancer 23:1921-1924
3. Aparicio A, Eads CA, Leong LA et al (2003) Phase I trial of continuous infusion 5-aza-2′-deoxycytidine. Cancer Chemother Pharmacol 51:231-239 12655442
4. Bosch van den J, Lübbert M, Verhoef G (2004) The effects of 5-aza-2′-deoxycytidine (decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes. Leuk Res 28:785-790 10.1016/j.leukres.2003.11.016
5. Bouchard J, Momparler RL (1983) Incorporation of 5-aza-2′-deoxycytidine 5′-triphosphate into DNA. Interactions with mammalian DNA polymerase and DNA methylase. Mol Pharmacol 24:109-114 6191192
6. Chabot G, Bouchard J, Momparler RL (1983) Kinetics of deamination of 5-aza-2′-deoxycytidine and cytosine arabinoside by human liver cytidine deaminase and its inhibition by 3-deazauridine, thymidine, and uracil arabinoside. Biochem Pharmacol 32:1327-1328 10.1016/ 0006-2952(83)90293-9
7. Constantinides PG, Taylor SM, Jones PA (1978) Phenotypic conversion of cultured mouse embryo cells by aza pyrimidine nucleosides. Dev Biol 66:57-71 10.1016/0012-1606(78)90273-7
8. Davies MJ, Jenkins PR, Prouse LSJ et al (1991) Structure of 2′-deoxy-5-azacytidine (decitabine) monohydrate. Acta Crystllogr C47:1418-1420
9. Egger G, Liang G, Aparicio A et al (2004) Epigenetics in human disease and prospects for epigenetic therapy. Nature 429:457-463 10.1038/ nature02625
10. Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, Bayar E, Lyons J, Rosenfeld CS, Cortes J, Kantarjian HM (2004) Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoetic malignancies. Blood 103:1635-1640 10.1182/blood-2003-03-0687
11. Jones PA, Taylor SM (1980) Cellular differentiation, cytidine analogs and DNA methylation. Cell 20:85-93 10.1016/0092-8674(80)90237-8
12. Jones PA, Taylor SM, Mohandas T et al (1982) Cell cycle-specific reactivation of an inactive X-chromosome locus by 5-azadeoxycytidine. Proc Natl Acad Sci U S A 79:1215-1219 6175964
13. Kantarjian HM, O'Brien SM, Keating M, Beran M, Estey E, Giralt S, Kornblau S, Rios MB, de Vos D, Talpaz M (1997) Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukaemia. Leukemia 11:1617-1620 10.1038/sj.leu.2400796
14. Kantarjian HM, Pinto A (eds) (1997) Workshop on the clinical results with decitabine (5-aza-2′-deoxycytabine) in hematologic malignancies. Leukemia 11(suppl monograph 1)
15. Kantarjian HM, O'Brien S, Cortes J, Giles FJ, Faderl S, Issa JP, Garcia-Manero G, Rios MB, Shan J, Andreeff M, Keating M, Talpaz M (2003) Results of decitabine (5-aza-2′-deoxycytidine) therapy in 130 patients with chronic myeloid leukaemia. Cancer 98:522-528 10.1002/ cncr.11543
16. Koshy M, Dom L, Bressler L, Molokie R, Lavelle D, Talischy N, Hoffman R, van Overveld W, DeSimone J (2000) 2′-deoxy-5-azacytidine and fetal hemoglobin induction in sickle cell anemia. Blood 96:2379-2384 11001887
17. Lima de M, Ravandi F, Shahjahan M, Andersson B, Couriel D, Donato M, Khouri I, Gajewski J, van Besien K, Champlin R, Giralt S, Kantarjian H (2003) Long-term follow-up of a phase I study of high dose decitabine, busulfan, and cyclophosphamide plus allogenic transplantation for the treatment of patients with leukemias. Cancer 97:1242-1247 10.1002/ cncr.11184
18. Lübbert M, Wijermans P, Kunzmann R, Verhoef G, Bosly A, Ravoet C, Andre M, Ferrant A (2001) Cytogenetic responses in high-risk myelodysplastic syndrome following low dose treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidine. Br J Haematol 114:349-357 10.1046/j.1365-2141.2001.02933.x
19. Lübbert M, Daskalakis M, Kunzmann R, Engelhardt M, Guo Y, Wijermans P (2004) Nonclonal neutrophil responses after successful treatment of myalodysplasia with low dose 5-aza-2′-deoxycytidine (decitabine). Leuk Res 28:1267-1271 10.1016/j.leukres.2004.04.002
20. Meulenbelt-Snijders SJ, Meulenbelt F, Paalman ACA et al (1984) Formulering van 5-aza-2′-deoxycytidine, een experimenteel cytostaticum. Pharm Weekbl 119:1186-1189
21. Momparler RL (1979) Pharmacology of 5-aza-2′-deoxycytidine. FEBS Symp 1979, Antimetab Biochem Biol Med 57:33-41
22. Momparler RL, Bouchard J, Onetto N, Rivard GE (1984) 5-Aza-2′-deoxycytidine therapy in patients with acute leukaemia inhibits DNA methylation. Leuk Res 8:181-185 10.1016/0145-2126(84)90141-3
23. Momparler RL, Rossi M, Bouchard J, Vacaro C, Momparler LF (1984) Kinetic interaction of 5-aza-2-deoxycytidine 5′-monophosphate and its 5′-triphosphate with deoxycytilate deaminase. Mol Pharmacol 25:436-438 6203026
24. Momparler RL, Rivard GE, Gyger M (1985) Clinical trial on 5-aza-2′-deoxycytidine in patients with acute leukaemia. Pharmacol Ther 30:277-286 10.1016/0163-7258(85)90052-X
25. RL Momparler D Vos de (eds) 1990 5-Aza-2′-deoxycytidine. Preclinical and clinical studies PCH Publications Haarlem, The Netherlands
26. Momparler RL, Bouffard DY, Momparler LF et al (1997) Pilot phase I-II study on 5-aza-2′-deoxycytidine (decitabine) in patients with metastaic lung cancer. Anticancer Drugs 8:358-368 9180389
27. Momparler RL, Eliopoulos N, Ayoub J (2000) Evaluation of an inhibitor of DNA methylation, 5-aza-2′-deoxycytidine for the treatment of lung cancer and the future role of gene therapy. Adv Exp Med Biol 465:433-446 10810647
28. Momparler RL, Ayoub J (2001) Potential of 5-aza-2′-deoxycytidine (decitabine) a potent inhibitor of DNA methylation for therapy of advanced non-small cell lung cancer. Lung Cancer 34(Suppl 4):S111-S115 10.1016/S0169-5002(01)00397-X
29. Pliml J, Sorm F (1964) Synthesis of 2′-deoxy-D-ribofuranosyl-5-azacytosine. Coll Czech Chem Commun 29:2576-2577
30. A Pinto V Attadia PP Fiore Di et al 1983 2′-Deoxy-5-azacytidine induces functional and morphological differentiation of a human erythroleukemic cell line (K562) In: MA Rich (ed) Leukemia review international 1 Marcel Dekker New York 207-208
31. Pinto A, Attadia V, Fusco A, Ferrara F, Spada OA, Di Fiore PP (1984) 5-Aza-2′-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias. Blood 64:922-929 6206904
32. Pinto A, Maio M, Attadia V, Zappacosta S, Cimino R (1984) Modulation of HLA-DR antigens expression in human myeloid leukaemic cells by cytarabine and 5-aza-2′-deoxycytidine. Lancet 2:867-868 10.1016/ S0140-6736(84)90900-0
33. Pinto A, Attadia V (1986) Leukemia therapy by differentiation inducers: the therapeutic concept of differentiation. Cancer J 1:54
34. Pinto A (eds) (1993) 5-Aza-2′-deoxycytidine and DNA methyltransferase inhibitors in the http://www.nytimes.com/2005/03/16/ nyregion/16ferrer.html treatment of myeloid leukemias and myelodysplastic syndromes: Biological aspects and clinical results. Leukemia 7(suppl 1)
35. Piskala A, Sorm F (1978) Anomeric 4-amino-1-(2-deoxy-D-erythro-pentofuranosyl)-S-triazin-2(1H)-ones (2′-deoxy-5-azacytidine and its α-D anomer). Synthesis of 5-azapyrimidine deoxyribonucleosides via acylglucosyl isocyanates. Nucleic Acid Chem 1:443-449
36. Piskala A, Synackova M, Tomankova H et al (1978) Direct synthesis of 5-azapyrimidine 2′-deoxyribonucleosides. Hydrolysis of 5-aza-2′-deoxycytidine. Nucleic Acid Res Spec Publ 4:109-113
37. Pohlmann P, DiLeone LP, Cancella AI et al (2002) Phase II trial of cisplatin plus decitabine, a new DNA hypomethylating agent, in patients with advanced squamous carcinoma of the cervix. Am J Clin Oncol 25:496-501 10.1097/00000421-200210000-00015
38. Ravandi F, Kantarjian H, Cohen A, Davis M, O'Brien S, Anderlini P, Andersson B, Claxton D, Donato M, Gajewski J, Khouri I, Korbling M, Ueno N, deVos D, Champlin R, Giralt S (2001) Decitabine with allogenic peripheral blood stem cell transplantation in the therapy of leukaemia relapse following a prior transplant: Results of a phase I study. Bone Marrow Transplant 27:1221-1225 10.1038/sj.bmt.1703028
39. DJ Richel 1990 Experimental therapy in Ara-C sensitive and resistant leukaemia, Ph.D. thesis University of Leiden The Netherlands
40. Richel DJ, Colly LP, Kluin-Nelemans JC, Willemze R (1991) The antileukaemic activity of 5-aza-2′-deoxycytidine (Aza-dC) in patients with relapsed acute leukaemia. Br J Cancer 64:144-148 1713050
41. Rivard GE, Momparler RL, Demers J et al (1981) Phase I study on 5-aza-2′-deoxycytidine in children with acute leukemia. Leuk Res 5:453-462 10.1016/0145-2126(81)90116-8
42. Ruter B, Wijermans PW, Lübbert M (2004) DNA methylation as a therapeutic target in hematologic disorders: Recent results in older patients with myodysplasia and acute myeloid leukaemia. Int J Hematol 80:128-135 10.1532/IJH97.04094
43. Sachs L (1978) The differentiation of myeloid leukaemia cells: New possibilities for therapy. Br J Haematol 40:509-517 365215
44. Schwartsmann G, Schunemann H, Gorini CN et al (2000) A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer. Invest New Drugs 18:83-91 10.1023/A:1006388031954
45. Sessa C, Ten Bokkel Huinink W, Stoter G, Renard J, Cavalli F (1990) Phase II study of 5-aza-2′-deoxycytidine in advanced ovarian cancer. Eur J Cancer 26:137-138 1691012
46. Sorm F, Vesely J (1968) Effect of 5-aza-2′-deoxycytidine against leukemic and hemopoietic tissues in AKR mice. Neoplasma 15:339-343 5684460
47. Thibault A, Figg WD, Bergan RC et al (1998) A phase II study of 5-aza-2′-deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer. Tumori 84:87-89 9619724
48. van Groeningen CJ, Leyva A, O'Brien AM, Gall HE, Pinedo HM (1986) Phase I and pharmacokinetic study of 5-aza-2′-deoxycytidine (NSC 127716) in cancer patients. Cancer Res 46:4831-4836 2425959
49. Vermorken JB, Tumolo S, Roozendaal KJ, Guastalla JP, Splinter TA, Renard J (1991) 5-Aza-2′-deoxycytidine in advanced or recurrent cancer of the cervix. Eur J Cancer 27:216-217 1709026
50. Wijermans P, Lübbert M, Verhoef G et al (2000) Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: A multicenter phase II study in elderly patients. J Clin Oncol 18:956-962 10694544
51. Willemze R, Stegman APA, Colly LP (1990) The use of 5-aza-2′-deoxycytidine (DAC) in adult patients with acute leukaemia (abstr). Haematologica 76:43